CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS - USD ($) shares in Thousands, $ in Thousands	12 Months Ended
	Jun. 30, 2016	Jun. 30, 2015	Jun. 30, 2014
Revenues:
License and milestone fees	$ 26,915	$ 57,815	$ 39,455
Royalty revenue	195	13,867	10,346
Non-cash royalty revenue related to the sale of future royalties	25,299	5,484
Research and development support	4,014	2,848	7,187
Clinical materials revenue	3,579	5,527	2,908
Total revenues	60,002	85,541	59,896
Operating Expenses:
Research and development	148,077	111,768	106,958
General and administrative	36,916	28,228	24,469
Total operating expenses	184,993	139,996	131,427
(Loss) income from operations	(124,991)	(54,455)	(71,531)
Investment income, net	325	69	44
Non-cash interest expense on liability related to the sale of future royalties and convertible senior notes	(20,130)	(5,437)
Other income (expense), net	(21)	(916)	123
Net (loss) income	$ (144,817)	$ (60,739)	$ (71,364)
Basic and diluted net (loss) income per common share (in dollars per share)	$ (1.67)	$ (0.71)	$ (0.83)
Basic and diluted weighted average common shares outstanding (in shares)	86,976	86,038	85,481
Total comprehensive (loss) income	$ (144,817)	$ (60,739)	$ (71,364)